Bridging tradition and innovation: electroacupuncture's impact on premature ovarian insufficiency.

Premature ovarian insufficiency (POI) occurs when a woman's ovaries stop functioning normally before age 40, leading to reduced fertility and early menopause. This condition is becoming increasingly common and affects both physical and emotional health. Currently, hormone replacement therapy is the main treatment, but long-term use carries risks including blood clots and increased breast cancer risk.

This comprehensive review examined how electroacupuncture—a technique combining traditional acupuncture with mild electrical stimulation—may help treat POI. Researchers analyzed both animal studies and clinical trials to understand how this therapy works. The findings suggest electroacupuncture may improve ovarian function through multiple pathways: it helps regulate the hormonal axis connecting the brain and ovaries, reduces inflammation, improves blood flow to the ovaries, balances the immune system, and may even influence beneficial gut bacteria.

At the cellular level, electroacupuncture appears to work by activating specific signaling pathways that protect ovarian cells from damage and death, while reducing oxidative stress that harms tissues. The review also examined various clinical studies showing that electroacupuncture treatments are both safe and effective for POI patients, with different treatment protocols showing positive results.

For women considering this therapy, these findings suggest electroacupuncture offers a promising alternative or complementary approach to conventional hormone therapy, potentially with fewer side effects. Future research using advanced technologies like genomics and metabolomics will help establish personalized treatment plans and further clarify how electroacupuncture works. If considering electroacupuncture for POI, consult with a licensed acupuncturist experienced in treating reproductive health conditions.

This systematic review examines electroacupuncture's mechanisms and efficacy in treating premature ovarian insufficiency (POI). The authors analyzed animal modeling methodologies and synthesized evidence demonstrating EA's multi-system regulatory effects on POI pathophysiology. Key mechanisms identified include: HPO axis regulation, neuroendocrine-immune network modulation, inflammatory response attenuation, improved ovarian perfusion, mesenchymal stem cell activation, and gut microbiota modification. Mechanistic analysis focused on PI3K/Akt and Hippo signaling pathways, anti-apoptotic effects, and oxidative stress reduction. Clinical evidence from multiple treatment protocols supports both efficacy and safety profiles, positioning EA as a viable alternative or adjunct to HRT without associated thrombotic or carcinogenic risks. The review advocates for future research integrating genomics, transcriptomics, and metabolomics to establish personalized, standardized treatment protocols. Clinical takeaway: EA demonstrates promising therapeutic potential for POI through multiple validated pathways, warranting integration into comprehensive fertility treatment plans with individualized point selection and stimulation parameters based on patient presentation.